Covered by CAS, CSA, IC, CAB Abstract, Global Health, Chinese Scientific Core Journal, Chinese Scientific Journal Effects of Irbesartan combined Atorvastatin on serum levels of Cys C, Hcy, TNF-α, ET, TGF-b1 in patients with early diabetic nephropathyn

摘要

Objective: To observe the effects of Irbesartan combined with Atorvastatin on early diabeticnephropathy patients’ serum Cys C, Hcy, TNF-α, ET and TGF-b1 levels. Methods: A totalof 60 early diabetic nephropathy patients were randomly divided into observation group(30 cases) and control group (30 cases). Observation group: Irbesartan combined withAtorvastatin; control group: patients were treated only by Irbesartan. Recording and comparingthe levels of Cys C, Hcy, TNF-α, ET and TGF-b1 before and after treatment. Results: (1)Before treatment, there was no statistically significant difference in the serum FBG, TG, Scr,BUN levels between the two groups. After treatment, compared with the same group beforetreatment, the serum TG, Scr, BUN levels of the two groups were significantly lower, and thoselevels of observation group were significantly better than the control group, the differencebetween two groups was statistically significant; (2) Before treatment, there was no statisticallysignificant difference in the serum Cys C, Hcy, TNF-α, ET, TGF-b1 levels between the twogroups. After treatment, compared with the same group before treatment, the serum Cys C,Hcy, TNF-α, ET, TGF-b1 levels of the two groups were significantly lower, and those levelsof observation group were significantly better than the control group, the difference betweentwo groups was statistically significant. Conclusion: Irbesartan combined with Atorvastatin forearly diabetic nephropathy patients can reduce the levels of serum Cys C, Hcy, TNF-α, ET,TGF-b1 and be beneficial to protect their nephritic function.